icon
View Focus Area

Lung Cancer Biomarker Testing ECHO

May 2021

-

January 2022

Orientation to the Comprehensive Lung Cancer Biomarker Testing ECHO Series

This session provided an overview of the ECHO model, along with providing a data level-set of the current burden of lung cancer in each state, and provide a brief introduction to lung cancer biomarker testing, including the current guidelines and approved FDA biomarker-driven treatments.

Understanding the Barriers to Biomarker Testing

This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.

Didactic Presenter

M. Patricia Rivera, MD

Pathways to Biomarker Testing (Patient Lens)

This session will provide an overview of the pathways to biomarker testing, through the lens of the patient, especially emphasizing the steps, the process, and the length of time involved.

Didactic Presenters

Raymond Osarogiagbon, MBBS, FACP

Suresh Ramalingam, MD, FASCO

Adequate Tissue for Sampling

This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.

Didactic Presenter

Gerard Silvestri, MD, MS, FCCP

Choice of Panel, Interpretation of Results, and Next Steps

This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).

Didactic Presenter

Ignacio Wistuba, MD

Improving Turnaround Time

This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.

Didactic Presenter

Lynette Sholl, MD, FCAP

What's Covered: Reimbursement and Coverage Policies from the Private and Public Payer Landscape

This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.

TBD

Our Experts

expert-head-shot

Pierre De Delva, MD

Section Chief of General Thoracic Surgery

Associate Program Director, Cardiothoracic Fellowship Program

expert-head-shot

Farhood Farjah, MD, MPH, FACS

Associate Professor of Surgery

Endowed Chair in Lung Cancer Research

Associate Medical Director for the Surgical Outcomes Research Center

expert-head-shot

Eric Flenaugh, MD, FCCP

Director of Advanced Diagnostic Interventional Pulmonary Medicine

Lung Nodule Clinic Physician Director

expert-head-shot

Zhonglin Hao, MD, PHD

Professor of Medicine and Cancer Biology and Medical Director

expert-head-shot

Bruce Johnson, MD, FASCO

Chief Clinical Research Officer at Dana-Farber/Harvard Cancer Center

Past-President of the American Society of Clinical Oncology

expert-head-shot

Adam Jones, MD

Radiation Oncology at Phoebe Putney Health System

Chair of the Georgia Lung Cancer Roundtable

expert-head-shot

Jill Kolesar, PharmD, MS, BCPS, FCCP

Director of the Precision Medicine Center, Co-Chair of the Molecular Tumor Board, and
Co-Leader of the Developmental Therapeutics Program

expert-head-shot

Timothy Mullett, MD, MBA, FAC

Medical Director, Markey Cancer Center Network Development

expert-head-shot

Raymond Osarogiagbon, MBBS, FACP

Director, Multidisciplinary Thoracic Oncology Program

expert-head-shot

Shadi Qasem, MD, MBA

Associate Professor and Director of Surgical Pathology

expert-head-shot

Suresh Ramalingam, MD, FASCO

Deputy Director, Winship Cancer Institute

Professor, Department of Hematology and Medical Oncology

Roberto C. Goizueta Distinguished Chair for Cancer Research

Director, Lung Cancer Program

expert-head-shot

M. Patricia Rivera, MD

Professor of Medicine at University of North Carolina at Chapel Hill

Secretary-Treasurer at the American Thoracic Society

expert-head-shot

Michal Senitko, MD, DAABIP

Section Chief, Interventional Pulmonology and Assistant Professor of Medicine and Surgery at the University of Mississippi Medical Center

Co-Director Lung Cancer Screening Program at UMMC Cancer Center and Research Institute

expert-head-shot

Lynette Sholl, MD, FCAP

Associate Professor of Pathology

expert-head-shot

Gerard Silvestri, MD, MS, FCCP

Hillenbrand Professor of Thoracic Oncology at Medical University of South Carolina

Immediate Past President of the American College of Chest Physicians

expert-head-shot

Robert Smith, PhD, FSBI

Senior Vice President, Cancer Screening

expert-head-shot

John Villano, MD, PHD

Director, Clinical Neuro-Oncology Research Program

expert-head-shot

Ignacio Wistuba, MD

Division Head and interim, Division of Pathology/Lab Medicine Professor

Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine

expert-head-shot

Ralph Zinner, MD

Director of the Thoracic Oncology Program

Collected Program Resources

Lung Cancer Biomarker Testing ECHO – Case Presentation Form

View More

PDF

Lung Cancer Biomarker Testing ECHO – Georgia – 6-9-2021 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Georgia – 6-9-2021 – Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Kentucky – 5-27-2021 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Kentucky – 5-27-2021 – Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Mississippi – 5-25-2021 – Recording

View More

Video

Lung Cancer Biomarker Testing ECHO – Mississippi – 5-25-2021 – Slides

View More

PDF

Lung Cancer Biomarker Testing ECHO – Session 0 – Resources

View More

PDF

Financial Support Provided By

  • Sponsor Logo

Get Involved

Complete the fields below to learn more about how the American Cancer Society uses the ECHO Model to fight cancer on all fronts, inquire about an upcoming ECHO, or to learn how you can join us in our mission to save lives, celebrate lives, and lead the fight for a world without cancer.

Contact Us

Involved-2

Support the American Cancer Society ECHO program with a contribution.

This Website is administered by the American Cancer Society, Inc. on behalf of the Office of Cancer Research & Implementation. Copyright © 2021 American Cancer Society ECHO American Cancer Society, Inc.

Privacy Policy